A61K 40/428
Undefined tumor antigens
Official title: {Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor}
A61K40/428 (Undefined tumor antigens) appears on 383 US grants and 793 published applications in this corpus.
Search patents in A61K- Granted patents
- 383
- Published applications
- 793
- Assignees
- 363
- Inventors
- 1,216
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1993 | 2 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 1 | 0 |
| 1997 | 2 | 0 |
| 1998 | 0 | 0 |
| 1999 | 1 | 0 |
| 2000 | 1 | 0 |
| 2001 | 6 | 6 |
| 2002 | 11 | 25 |
| 2003 | 7 | 26 |
| 2004 | 5 | 14 |
| 2005 | 4 | 18 |
| 2006 | 4 | 8 |
| 2007 | 4 | 14 |
| 2008 | 0 | 9 |
| 2009 | 4 | 14 |
| 2010 | 9 | 17 |
| 2011 | 7 | 21 |
| 2012 | 9 | 16 |
| 2013 | 6 | 9 |
| 2014 | 10 | 14 |
| 2015 | 8 | 13 |
| 2016 | 8 | 24 |
| 2017 | 16 | 23 |
| 2018 | 6 | 28 |
| 2019 | 21 | 42 |
| 2020 | 28 | 56 |
| 2021 | 43 | 83 |
| 2022 | 51 | 104 |
| 2023 | 20 | 67 |
| 2024 | 23 | 72 |
| 2025 | 38 | 46 |
| 2026 | 28 | 24 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Compositions and methods for treating cancer6 Oct 2026US 12,753,236 B2Alpha Beta Holdings, LLC
- Fixed ratio ex vivo activated mixed lymphocyte products for use in the treatment of cancer22 Sep 2026US 12,742,153 B2Children's National Medical Center
- Trojan circulating tumor cells8 Sep 2026US 12,728,140 B2Astrin Biosciences, Inc.
- Media and methods for differentiating natural killer cells1 Sep 2026US 12,723,233 B2Stemcell Technologies Canada Inc.
- Tumor immunotherapy composition based on antigen-presenting cells activated by attenuated listeria monocytogenes, preparation method therefor and application thereof11 Aug 2026US 12,702,681 B2Shanghai RoyalTech Med CO., Ltd
- Generation of chimeric antigen receptor (car)-primary nk cells for cancer immunotherapy using a combination of cas9/rnp and aav viruses8 Oct 2026US 2026/0308628 A1Research Institute At Nationwide Children's Hospital
- Il-13/il-4 superkines: immune cell targeting constructs and methods of use thereof1 Oct 2026US 2026/0297151 A1Medicenna Therapeutics Inc.
- Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy17 Sep 2026US 2026/0272985 A1Iovance Biotherapeutics, Inc.
- Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy17 Sep 2026US 2026/0272986 A1Iovance Biotherapeutics, Inc.
- Methods for expansion of tumor infiltrating lymphocytes and use thereof3 Sep 2026US 2026/0258130 A1Board of Regents, The University of Texas System
Most cited
By later US patents
- Simultaneous stimulation and concentration of cells383US 6,905,874 B2XCYTE Therapies, Inc. · 2005
- Compositions and methods for identifying antigens which elicit an immune response89US 6,500,641 B1Wake Forest University School of Medicine · 2002
- Method for the production of activated marked tumor-specific T cells and use thereof in treatment of tumors64US 6,399,054 B1Science Park RAF S.p.A. · 2002
- Compounds for therapy and diagnosis of lung cancer and methods for their use63US 6,444,425 B1Corixa Corporation · 2002
- Directed maturation of stem cells and production of programmable antigen presenting dentritic cells therefrom57US 6,251,665 B12001